Pharma's GLP-1 Drug Bubble: Gold Rush or Crash?

Pharmas Gold Rush: The Bubble Effect of Weight Loss and Diabetes Drugs Pharma companies are raking in big returns from weight loss and diabetes drugs like Wegovy and Zepbound, with a Deloitte report warning of a bubble effect. These GLP-one drugs account for 38% of projected cash flows starting in 2025, but without them, industry returns drop to just 2.9%. Experts call it a bubble due to overconcentration, with 54 mega-blockbusters driving 70% of peak sales. These drugs show promise beyond weight loss, but with competition crowding the market, the big question is whether pharma will double down on this gold rush or seek the next breakthrough to avoid the crash. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/c78b3a4009199166